Advertisement

Breast Cancer Research and Treatment

, Volume 158, Issue 2, pp 277–286 | Cite as

Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1

  • Ming Yang
  • Wendi Teng
  • Yue Qu
  • Haiyong Wang
  • Qipeng YuanEmail author
Preclinical study

Abstract

Sulforaphene (SFE, 4-methylsufinyl-3-butenyl isothiocyanate) is a member of isothiocyanates, which is derived from radish seeds. It has shown that multiple isothiocyanates, such as sulforaphane, can effectively inhibit cancer cell proliferation in vitro and in vivo. However, it is still largely unknown if SFE could impact breast cancer. In this study, we investigated the anticancer effects of SFE on triple negative breast cancer (TNBC) via a series of in vitro and in vivo assays. We found that SFE can significantly inhibit cell proliferation in multiple TNBC cell lines through inducing G2/M phase arrest as well as cell apoptosis. Nude mice xenograft assays support the anti-TNBC role of SFE in vivo. Interestingly, SFE can repress expression of cyclinB1, Cdc2, and phosphorylated Cdc2, and, then, induced G2/M phase arrest of TNBC cells. To identify SFE target genes, we detected genome-wide gene expression changes through gene expression profiling and observed 27 upregulated and 18 downregulated genes in MDA-MB-453 cells treated with SFE. Among these genes, Egr1 was successfully validated as a consistently activated gene after SFE treatment in TNBC MDA-MB-453 and MDA-MB-436 cells. Egr1 overexpression inhibited proliferation of TNBC cells. However, Egr1 knockdown using siRNAs significantly promoted TNBC cell growth, indicating the tumor suppressor nature of Egr1. In sum, we for the first time found that SFE might be a potential anti-TNBC natural compound and its antiproliferation effects might be mediated by tumor suppressor Egr1.

Keywords

Sulforaphene Triple Negative Breast Cancer Isothiocyanate Egr1 

Notes

Grant support

This work was supported by the National High-Tech Research and Development Program of China (2015AA020950); the Fundamental Research Funds for the Central Universities (YS1407); the open project of State Key Laboratory of Molecular Oncology (SKL-KF-2015-05); Program for Changjiang Scholars and Innovative Research Team in University (IRT13045); Innovation and Promotion Project of Beijing University of Chemical Technology.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. Cancer J Clin 65:5–29CrossRefGoogle Scholar
  2. 2.
    Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS (2016) Breast cancer risk assessment: moving beyond BRCA1 and 2. Semin Radiat Oncol 26:3–8CrossRefPubMedGoogle Scholar
  3. 3.
    Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J Clin Oncol 23:7350–7360CrossRefPubMedGoogle Scholar
  4. 4.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61:69–90CrossRefGoogle Scholar
  5. 5.
    Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL (2014) Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74:4822–4835CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    D’Amato NC, Rogers TJ, Gordon MA, Greene LI (2015) A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res 75:4651–4664CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Witherby S, Rizack T, Sakr BJ, Legare RD, Sikov WM (2016) Advances in medical management of early stage and advanced breast cancer: 2015. Semin Radiat Oncol 26:59–70CrossRefPubMedGoogle Scholar
  8. 8.
    Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA (1996) Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomark Prev 5:733–748Google Scholar
  9. 9.
    Kuang P, Song D, Yuan Q, Yi R, Lv X, Liang H (2013) Separation and purification of sulforaphene from radish seeds using macroporous resin and preparative high-performance liquid chromatography. Food Chem 136:342–347CrossRefPubMedGoogle Scholar
  10. 10.
    Pocasap P, Weerapreeyakul N, Barusrux S (2013) Cancer preventive effect of Thai rat-tailed radish (Raphanus sativus L. var. caudatus Alef). J Funct Food 5:1372–1381CrossRefGoogle Scholar
  11. 11.
    Papi A, Orlandi M, Bartolini G, Barillari J, Iori R, Paolini M, Ferroni F, Grazia Fumo M, Pedulli GF, Valgimigli L (2008) Cytotoxic and antioxidant activity of 4-methylthio-3-butenyl isothiocyanate from Raphanus sativus L. (Kaiware Daikon) sprouts. J Agric Food Chem 56:875–883CrossRefPubMedGoogle Scholar
  12. 12.
    Nastruzzi C, Cortesi R, Esposito E, Menegatti E, Leoni O, Iori R, Palmieri S (2000) In vitro antiproliferative activity of isothiocyanates and nitriles generated by myrosinase-mediated hydrolysis of glucosinolates from seeds of cruciferous vegetables. J Agric Food Chem 48:3572–3575CrossRefPubMedGoogle Scholar
  13. 13.
    Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG (2004) Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 134:1134–1138PubMedGoogle Scholar
  14. 14.
    Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W (2003) Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res 63:3980–3986PubMedGoogle Scholar
  15. 15.
    Terry P, Wolk A, Persson I, Magnusson C (2001) Brassica vegetables and breast cancer risk. J Am Med Assoc 285:2975–2977CrossRefGoogle Scholar
  16. 16.
    Zhao C, Yue B, Liu H, Sun C, Li W, Qu X (2012) SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicol Appl Pharmacol 262:293–300CrossRefPubMedGoogle Scholar
  17. 17.
    Bonnesen C, Eggleston IM, Hayes JD (2001) Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 61:6120–6130PubMedGoogle Scholar
  18. 18.
    Choi S, Lew KL, Xiao H, Herman-Antosiewicz A (2007) D, L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 28:151–162CrossRefPubMedGoogle Scholar
  19. 19.
    Gamet Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60:1426–1433PubMedGoogle Scholar
  20. 20.
    Hu K, Qi YJ, Zhao J, Jiang HF, Chen X, Ren J (2013) Synthesis and biological evaluation of sulforaphane derivatives as potential antitumor agents. Eur J Med Chem 64:529–539CrossRefPubMedGoogle Scholar
  21. 21.
    Chang CC, Hung CM, Yang YR, Lee MJ, Hsu YC (2013) Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells. J Ovarian Res 6:41CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gould KA, Tochacek M, Schaffer BS, Reindl TM, Murrin CR, Lachel CM, VanderWoude EA, Pennington KL, Flood LA, Bynote KK et al (2004) Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 168:2113–2125CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N (2003) Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr Med Chem Anti 3:1–14CrossRefGoogle Scholar
  24. 24.
    Stark GR, Taylor WR (2006) Control of the G2/M transition. Mol Biotechnol 32:227–248CrossRefPubMedGoogle Scholar
  25. 25.
    Choi YH, Yoo YH (2012) Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep 28:2163–2169PubMedGoogle Scholar
  26. 26.
    Han SJ, Conti M (2006) New pathways from PKA to the Cdc2/cyclin B complex in oocytes: wee1B as a potential PKA substrate. Cell Cycle 5:227–231CrossRefPubMedGoogle Scholar
  27. 27.
    Milbrandt J (1987) A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 238:797–799CrossRefPubMedGoogle Scholar
  28. 28.
    Bhattacharyya S, Fang F, Tourtellotte W, Varga J (2013) Egr1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). Am J Pathol 229:286–297CrossRefGoogle Scholar
  29. 29.
    Rong Y, Hu F, Huang RP, Mackman N, Horowitz JM, Jensen RL et al (2006) Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1 – independent mechanisms. Cancer Res 66:7067–7074CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Thiel G, Cibelli G (2002) Regulation of life and death by the zinc finger transcription factor Egr1. J Cell Physiol 193:287–292CrossRefPubMedGoogle Scholar
  31. 31.
    Redmond KL, Crawford NT, Farmer H, D’Costa ZC, O’Brien GJ, Buckley NE (2010) T-box 2 represses NDRG1 through an Egr1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene 29:3252–3262CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ming Yang
    • 1
  • Wendi Teng
    • 1
  • Yue Qu
    • 1
  • Haiyong Wang
    • 1
  • Qipeng Yuan
    • 1
    Email author
  1. 1.State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and TechnologyBeijing University of Chemical TechnologyBeijingChina

Personalised recommendations